Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Li J Yu"'
Autor:
Mehdi Bouhaddou, Li J. Yu, Serena Lunardi, Spyros K. Stamatelos, Fiona Mack, James M. Gallo, Marc R. Birtwistle, Antje‐Christine Walz
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 2, Pp 419-429 (2020)
Reliably predicting in vivo efficacy from in vitro data would facilitate drug development by reducing animal usage and guiding drug dosing in human clinical trials. However, such prediction remains challenging. Here, we built a quantitative pharmacok
Externí odkaz:
https://doaj.org/article/4f66816e62d5476caa64a75265e11815
Publikováno v:
The AAPS Journal. 18:1464-1474
Alectinib, a lipophilic, basic, anaplastic lymphoma kinase (ALK) inhibitor with very low aqueous solubility, has received Food and Drug Administration-accelerated approval for the treatment of patients with ALK+ non-small-cell lung cancer. This paper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df34b80a908c25d50de1721e7ef90ca7
https://doi.org/10.1208/s12248-016-9957-3
https://doi.org/10.1208/s12248-016-9957-3
Publikováno v:
Neurophysiology. Dec2014, Vol. 46 Issue 6, p501-506. 6p.
Autor:
Spyros K. Stamatelos, Serena Lunardi, Marc R. Birtwistle, Fiona Mack, Antje-Christine Walz, James M. Gallo, Mehdi Bouhaddou, Li J. Yu
Publikováno v:
Cancer Research. 78:2796-2796
Epigenetic modulators are increasing in prominence as potential cancer therapies. These drugs achieve their effectiveness by inducing transcriptional changes that can inhibit cancer progression. Here, we focus on a potent and selective covalent small
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::adbace7377b0ea728e22303b6baaacc2
https://doi.org/10.1158/1538-7445.am2018-2796
https://doi.org/10.1158/1538-7445.am2018-2796
Autor:
Michael Scott Visser, Michael P. DeNinno, Melissa P. Andrews, Andrew Simon Bell, Michael John Palmer, Nan Eshelby, Cynthia Eller-Zarbo, John B. Etienne, Yue Chen, E. Michael Gibbs, William J. Zavadoski, Li J. Yu, Dianna E. Moore
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 19:2537-2541
Starting from a non-selective pyrazolo-pyrimidone lead, the sequential use of parallel medicinal chemistry and directed synthesis led to the discovery of potent, highly selective, and orally bioavailable PDE9 inhibitors. The availability of these too
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90579384bdc00653d5f3b8ed65d6fc3e
https://doi.org/10.1016/j.bmcl.2009.03.024
https://doi.org/10.1016/j.bmcl.2009.03.024
Autor:
Adrian J. Fretland, Mary Palacios, Dietrich Tuerck, Li J Yu, Jianguo Zhi, Micaela B. Reddy, Sazzad Hussain, Faye Vazvaei, Neil Parrott, Kelli J Glenn
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 46(8)
1. Idasanutlin (RG7388) is a potent p53-MDM2 antagonist currently in clinical development for treatment of cancer. The purpose of the present studies was to investigate the cause of marked decrease in plasma exposure after repeated oral administratio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4de6355ef99750d71696739caba152c
https://pubmed.ncbi.nlm.nih.gov/26586447
https://pubmed.ncbi.nlm.nih.gov/26586447
Autor:
Martha Kirby, Reiko Horai, Alan Sher, Jennifer L. Cannons, Allen W. Cheever, Pamela L. Schwartzberg, Shane Crotty, Dragana Jankovic, Li J. Yu, Stacie M. Anderson
Publikováno v:
The Journal of Experimental Medicine
X-linked lymphoproliferative disease is caused by mutations affecting SH2D1A/SAP, an adaptor that recruits Fyn to signal lymphocyte activation molecule (SLAM)-related receptors. After infection, SLAM-associated protein (SAP)−/− mice show increase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7438d447be7932a8ac723af9954e9a47
https://doi.org/10.1084/jem.20052097
https://doi.org/10.1084/jem.20052097
Autor:
Koteswara R. Chintalacharuvu, Kunihiko Kobayashi, Sherie L. Morrison, Nishant Bhola, Li J. Yu, Christine Z. Fernandez
Publikováno v:
The Journal of Immunology. 169:5072-5077
In humans, there are two subclasses of IgA, IgA1 and IgA2, with IgA2 existing as three allotypes, IgA2m(1), IgA2m(2) and IgA2(n). In IgA1, Cys133 in CH1 forms the disulfide bond to the L chain. Our previous studies indicated that in IgA2 lacking Cys1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62df1bc717d955ff3af35d5ca1f17f9d
https://doi.org/10.4049/jimmunol.169.9.5072
https://doi.org/10.4049/jimmunol.169.9.5072
Publikováno v:
mAbs. 2(3)
The development and production of recombinant monoclonal antibodies is well established. Although most of these are IgGs, there is also great interest in producing recombinant IgAs since this isotype plays a critical role in providing immunologic pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53a9700188b3ba112cff0372b173f0d0
https://pubmed.ncbi.nlm.nih.gov/20431350
https://pubmed.ncbi.nlm.nih.gov/20431350